American Journal Of Drug And Alcohol Abuse

杂志介绍

American Journal Of Drug And Alcohol Abuse杂志介绍

《American Journal Of Drug And Alcohol Abuse》是一本以English为主的未开放获取国际优秀期刊，中文名称美国药物和酒精滥用杂志，本刊主要出版、报道医学-PSYCHOLOGY, CLINICAL领域的研究动态以及在该领域取得的各方面的经验和科研成果，介绍该领域有关本专业的最新进展，探讨行业发展的思路和方法，以促进学术信息交流，提高行业发展。该刊已被国际权威数据库SCIE、SSCI收录，为该领域相关学科的发展起到了良好的推动作用，也得到了本专业人员的广泛认可。该刊最新影响因子为2.7，最新CiteScore 指数为4.7。

本刊近期中国学者发表的论文主要有：

• Effects of ketamine use on psychotic disorders and symptoms in male, methamphetamine-dependent subjects.

  Author: Dong H^1,2, Yang C², Shen Y², Liu L³, Liu M², Hao W².

• Nonconformist tendencies related to risky choices in female methamphetamine abstainers.

  Author: Wei S^1,2, Liu Q^3,4, Harrington M⁴, Sun J⁵, Yu H^2,6, Han J⁷, Hao M⁷, Wu H^2,8,9, Liu X^2,8.

• The association of HTR3A mRNA expression and craving in Han Chinese alcohol-dependent patients: a preliminary study.

  Author: Xu YH, Wang LL, Shi L, Lei JP, Miao Q, Liu TQ, Hao W, Lu L, Zhang RL.

• Ethanol alters the expression of ion channel genes in Daphnia pulex.

  Author: Hu AM, Zhu T, Dong L, Luo NF, Du GZ.

英文介绍

American Journal Of Drug And Alcohol Abuse杂志英文介绍

The American Journal of Drug and Alcohol Abuse (AJDAA) is an international journal published six times per year and provides an important and stimulating venue for the exchange of ideas between the researchers working in diverse areas, including public policy, epidemiology, neurobiology, and the treatment of addictive disorders. AJDAA includes a wide range of translational research, covering preclinical and clinical aspects of the field. AJDAA covers these topics with focused data presentations and authoritative reviews of timely developments in our field. Manuscripts exploring addictions other than substance use disorders are encouraged. Reviews and Perspectives of emerging fields are given priority consideration.

Areas of particular interest include: public health policy; novel research methodologies; human and animal pharmacology; human translational studies, including neuroimaging; pharmacological and behavioral treatments; new modalities of care; molecular and family genetic studies; medicinal use of substances traditionally considered substances of abuse.